source
- Novo Nordisk's ziltivekimab fails phase 3 trial, jeopardizing CKD programNovo Nordisk reported that its phase 3 Zeus trial of the IL‑6 ligand antibody ziltivekimab did not meet its primary endpoint, a setback for the drug's development. The study enrolled more than 6,3…
- Labcorp reports Q2 sales of $3.73 billion, lifts full-year revenue outlook despite missing consensusLabcorp announced second‑quarter revenue of $3.73 billion, up from $3.53 billion a year earlier, driven by strong performance across its core businesses. The Diagnostics division grew 5.5% to $2.9…